This paper investigates the effect of different patent regimes on R&D investment and social welfare in a duopoly market with uncertain R&D process. We find that strong patent protection increases R&D investment of at least one firm but whether both firms’ R&D investment will be more under strong patent protection is ambiguous. While ex-ante welfare is more likely to be higher under strong paten...

Nearly every industry is increasingly reliant on patent protections, and the future of entire industries and even countries can be analyzed and predicted based on patent development. Countries are responding to the rapid development of RFID applications by aggressively protecting pursuing and protecting RFID innovations. This study examines a number of patent indicators to predict and explain f...

We seek to advance scholarship in patent strategy by presenting a set of organizing theoretical perspectives to guide future research. The domain of patent strategy primarily encompasses patenting, licensing, and enforcement decisions. Patent strategy also entails a set of nested choices, where future opportunities are only available by building prior positions, which thus become a source of dy...

This paper investigates the effect of different patent regimes on R&D investment and social welfare in a duopoly market with uncertain R&D process. We find that strong patent protection increases R&D investment of at least one firm but whether both firms’ R&D investment will be more under strong patent protection is ambiguous. While ex-ante welfare is more likely to be higher under strong paten...

Previously, we proposed an approach for corporate decision making with self-organizing patent maps labeled by technical terms and AHP. First, we extracted keywords by text mining to transform patent documents into feature vectors of the companies. Second, we inputted the feature matrix of technical terms and company names into self-organizing maps to create patent maps labeled by the technical ...

BACKGROUND Lack of access to insulin and poor health outcomes are issues for both low and high income countries. This has been accompanied by a shift from relatively inexpensive human insulin to its more expensive analogs, marketed by three to four main global players. Nonetheless, patent-based market exclusivities are beginning to expire there for the first generation insulin analogs. This pap...